<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="24d75b58-bafb-4440-b8d7-4f4079c08b0b"><labelDrug name="PLETAL"><Normalization><mmtx cui="C0722654" preferredWord="Pletal" semType="phsu, orch"/></Normalization></labelDrug><generic name="cilostazol"/><sentence id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.1" text="PLETAL (cilostazol) tablet" type="negative"><entity charOffset="8:18" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.1.e.0" text="cilostazol" type="Biomedical_Entity"><Normalization><mmtx cui="C0055729" phraseText="(cilostazol" preferredWord="cilostazol" semType="phsu, orch"/><RxNorm RxCui="21107"/></Normalization></entity><entity charOffset="0:6" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.1.e.1" text="pletal" type="Biomedical_Entity"><Normalization><mmtx cui="C0722654" phraseText="PLETAL" preferredWord="Pletal" semType="phsu, orch"/><RxNorm RxCui="219267"/></Normalization></entity><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.1.e.1" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.1.e.0"/></sentence><sentence id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.3" text="Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. " type="negative"><entity charOffset="46:81" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.3.e.0" text="inhibitors phosphodiesterase iii" type="Biomedical_Entity"><Normalization><mmtx cui="C3537188" phraseText="inhibitors of phosphodiesterase III." preferredWord="Phosphodiesterase 3 Inhibitor [EPC]" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="0:10" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.3.e.1" text="cilostazol" type="Biomedical_Entity"><Normalization><mmtx cui="C0055729" phraseText="Cilostazol" preferredWord="cilostazol" semType="phsu, orch"/><RxNorm RxCui="21107"/></Normalization></entity><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.3.e.1" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.3.e.0"/></sentence><sentence id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.14" text="There is limited information with respect to the efficacy or safety of the concurrent use of cilostazol and clopidogrel, a platelet-aggregation inhibiting drug indicated for use in patients with peripheral arterial disease. " type="negative"><entity charOffset="93:103" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.14.e.0" text="cilostazol" type="Biomedical_Entity"><Normalization><mmtx cui="C0055729" phraseText="safety of the concurrent use of cilostazol" preferredWord="cilostazol" semType="phsu, orch"/><RxNorm RxCui="21107"/></Normalization></entity><entity charOffset="108:119" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.14.e.1" text="clopidogrel" type="Biomedical_Entity"><Normalization><mmtx cui="C0070166" phraseText="clopidogrel," preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.14.e.0" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.14.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15" lineNumber="19" text="Although it cannot be determined whether there was an additive effect on bleeding times during concomitant administration with cilostazol and clopidogrel, caution is advised for checking bleeding times during coadministration." type="regular"><entity charOffset="127:137" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.e.0" text="cilostazol" type="Drug"><Normalization><mmtx cui="C0055729" phraseText="with cilostazol" preferredWord="cilostazol" semType="phsu, orch"/><RxNorm RxCui="21107"/></Normalization></entity><entity charOffset="142:153" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.e.1" text="clopidogrel" type="Drug"><Normalization><mmtx cui="C0070166" phraseText="clopidogrel," preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="155:162" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.e.2" text="caution" type="Caution_Interaction"/><drugInteraction id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.ddi.1"><interaction trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.e.0" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.e.1" trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.15.e.2" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="6" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17" lineNumber="23" text="Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. " type="regular"><entity charOffset="72:79" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.0" text="caution" type="Caution_Interaction"/><entity charOffset="105:111" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.2" text="PLETAL" type="Drug"><Normalization><mmtx cui="C0722654" phraseText="PLETAL" preferredWord="Pletal" semType="phsu, orch"/><RxNorm RxCui="219267"/></Normalization></entity><entity charOffset="135:155" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.3" text="inhibitors of CYP3A4" type="Drug_Class"><Normalization><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="164:176" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.4" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="such as ketoconazole" preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="181:193" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.5" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="erythromycin" preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="197:218" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.6" text="inhibitors of CYP2C19" type="Drug_Class"><Normalization><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="227:237" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.7" text="omeprazole" type="Drug"><Normalization><mmtx cui="C0028978" phraseText="such as omeprazole." preferredWord="Omeprazole" semType="phsu, orch"/><RxNorm RxCui="7646"/></Normalization></entity><drugClassMembership drug="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.4" drugClass="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.3"/><drugClassMembership drug="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.5" drugClass="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.3"/><drugClassMembership drug="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.7" drugClass="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.6"/><drugInteraction id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.ddi.1"><interaction trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.6"/></relation><relation type="hasObject"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.2" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.3" trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.2" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.6" trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.3" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.17.e.6"/></sentence><sentence biomedicalEntities="3" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18" lineNumber="23" text="Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. " type="regular"><entity charOffset="47:57" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.0" text="omeprazole" type="Drug"><Normalization><mmtx cui="C0028978" phraseText="that omeprazole" preferredWord="Omeprazole" semType="phsu, orch"/><RxNorm RxCui="7646"/></Normalization></entity><entity charOffset="62:74" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.1" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="erythromycin significantly" preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="89:120" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.2" text="increased the systemic exposure" type="Increase_Interaction"/><entity charOffset="124:134" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.4" text="cilostazol" type="Drug"><Normalization><mmtx cui="C0055729" phraseText="the systemic exposure of cilostazol" preferredWord="cilostazol" semType="phsu, orch"/><RxNorm RxCui="21107"/></Normalization></entity><drugInteraction id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.ddi.1"><interaction trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.1" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.4" trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.2" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.0" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.4" trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.2" type="Increase_Interaction"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.0" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19" lineNumber="23" text="Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions). " type="regular"><entity charOffset="133:152" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.0" text="inhibitor of CYP3A4" type="Drug_Class"><Normalization><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="119:128" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.1" text="diltiazem" type="Drug"><Normalization><mmtx cui="C0012373" phraseText="treated with diltiazem," preferredWord="Diltiazem" semType="phsu, orch"/><RxNorm RxCui="203211"/></Normalization></entity><entity charOffset="42:63" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.3" text="higher concentrations" type="Increase_Interaction"/><entity charOffset="67:77" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.5" text="cilostazol" type="Drug"><Normalization><mmtx cui="C0055729" phraseText="higher concentrations of cilostazol" preferredWord="cilostazol" semType="phsu, orch"/><RxNorm RxCui="21107"/></Normalization></entity><drugClassMembership drug="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.1" drugClass="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.0"/><drugInteraction id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.ddi.1"><interaction trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.3"><relations><relation type="hasPrecipitant"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.5"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.5" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.1" trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.3" type="Increase_Interaction"/></sentence><sentence id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20" text="PLETAL does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition." type="negative"><entity charOffset="120:130" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20.e.0" text="lovastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0024027" phraseText="no effect on lovastatin," preferredWord="Lovastatin" semType="phsu, orch"/><RxNorm RxCui="6472"/></Normalization></entity><entity charOffset="0:6" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20.e.1" text="pletal" type="Biomedical_Entity"><Normalization><mmtx cui="C0722654" phraseText="PLETAL" preferredWord="Pletal" semType="phsu, orch"/><RxNorm RxCui="219267"/></Normalization></entity><entity charOffset="52:73" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20.e.2" text="blood drugs" type="Biomedical_Entity"><Normalization><mmtx cui="C0018938" phraseText="increased blood levels of drugs" preferredWord="Hematologic Agents" semType="phsu"/><RxNorm RxCui="1629"/></Normalization></entity><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20.e.1" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20.e.0"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20.e.2" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20.e.0"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20.e.1" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.20.e.2"/></sentence><sentence id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.24" text="Platelet aggregability returns to normal within 96 hours of stopping PLETAL. " type="negative"><entity charOffset="69:75" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.24.e.0" text="pletal" type="Biomedical_Entity"><Normalization><mmtx cui="C0722654" phraseText="of stopping PLETAL." preferredWord="Pletal" semType="phsu, orch"/><RxNorm RxCui="219267"/></Normalization></entity><entity charOffset="60:68" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.24.e.1" text="stopping" type="Biomedical_Entity"><Normalization><mmtx cui="C0723457" phraseText="of stopping PLETAL." preferredWord="Stop brand of fluoride" semType="inch, phsu"/><RxNorm RxCui="220037"/></Normalization></entity><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.24.e.1" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.24.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25" lineNumber="27" text="Caution is advised in patients receiving both PLETAL and any other antiplatelet agent, or in patients with thrombocytopenia." type="regular"><entity charOffset="0:7" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.e.0" text="Caution" type="Caution_Interaction"/><entity charOffset="46:52" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.e.2" text="PLETAL" type="Drug"><Normalization><mmtx cui="C0722654" phraseText="both PLETAL" preferredWord="Pletal" semType="phsu, orch"/><RxNorm RxCui="219267"/></Normalization></entity><entity charOffset="67:85" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.e.3" text="antiplatelet agent" type="Drug_Class"><Normalization><mmtx cui="C0085826" phraseText="any other antiplatelet agent," preferredWord="Antiplatelet Agents" semType="phsu"/><RxNorm RxCui="42539"/></Normalization></entity><drugInteraction id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.ddi.1"><interaction trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.e.0"><relations><relation type="hasObject"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.e.2" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.e.3" trigger="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.25.e.0" type="Caution_Interaction"/></sentence><sentence id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28" text="A dose of 50 mg b.i.d. should be considered during coadministration of such inhibitors of CYP3A4 as ketoconazole, itraconazole, erythromycin and diltiazem, and during coadministration of such inhibitors of CYP2C19 as omeprazole." type="negative"><entity charOffset="145:154" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.0" text="diltiazem" type="Biomedical_Entity"><Normalization><mmtx cui="C0012373" phraseText="diltiazem," preferredWord="Diltiazem" semType="phsu, orch"/><RxNorm RxCui="203211"/></Normalization></entity><entity charOffset="217:227" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.1" text="omeprazole" type="Biomedical_Entity"><Normalization><mmtx cui="C0028978" phraseText="as omeprazole." preferredWord="Omeprazole" semType="phsu, orch"/><RxNorm RxCui="7646"/></Normalization></entity><entity charOffset="128:140" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.2" text="erythromycin" type="Biomedical_Entity"><Normalization><mmtx cui="C0014806" phraseText="erythromycin" preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="114:126" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.3" text="itraconazole" type="Biomedical_Entity"><Normalization><mmtx cui="C0064113" phraseText="itraconazole," preferredWord="Itraconazole" semType="phsu, orch"/><RxNorm RxCui="28031"/></Normalization></entity><entity charOffset="0:21" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.4" text="a d" type="Biomedical_Entity"><Normalization><mmtx cui="C0718133" phraseText="A dose of 50 mg b.i.d." preferredWord="a &amp; d" semType="phsu, orch, vita"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="100:112" id="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.5" text="ketoconazole" type="Biomedical_Entity"><Normalization><mmtx cui="C0022625" phraseText="as ketoconazole," preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.0" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.1"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.2" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.0"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.3" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.0"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.4" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.0"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.5" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.0"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.2" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.1"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.3" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.1"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.4" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.1"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.5" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.1"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.3" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.2"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.4" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.2"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.5" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.2"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.4" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.3"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.5" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.3"/><pair ddi="false" e1="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.4" e2="Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.28.e.5"/></sentence><positiveExamples number="7"/><negativeExamples number="24"/></document>